SINGAPORE – 17 Jul 2024 – PairX Bio was announced as the winner of the Amgen x NSG BioLabs Golden Ticket Award. As one of the top 6 finalist companies, Dr. Cheuk Ka Tong, Chief of Staff at Tikva Allocell, represented the company at a poster presentation at the award ceremony, sharing about Tikva’s allogeneic Epstein-Barr virus-specific T (EBVST) cell platform technology and its lead product, the B7-H3-targeting EBVST cell enhanced with an engineered variant of the SerpinB9 protein to improve cell persistence and anti-tumor efficacy.
The award ceremony was packed with excitement with the announcements of continuation of the Golden Ticket Award for another three years, and planned expansion of NSG BioLabs into the new science hub, Geneo. There was also a lively panel discussion by Dr. Alan Russell (VP of Research, Therapeutic Discovery, Amgen), Dr. Yvonne Koh (VP of Therapeutics, ClavystBio) Dr. David Epstein (Co-Founder, CEO and President, PairX Bio), and moderated by Mr. Jeffrey Lu (Co-Founder and CEO, Engine Biosciences), on the importance of a vibrant research environment, private-public partnerships and nurturing talents to cultivate entrepreneurship and grow the biotech ecosystem in Singapore.
Tikva Allocell is proud to be a part of this community innovating for the improvement of healthcare. Big congratulations to PairX Bio and fellow finalist companies!
Tong Cheuk Ka, PhD
Chief of Staff
At Tikva Allocell, Cheuk Ka establishes strategic partnerships to advance the development of cell therapies for the treatment of cancers. She has led cross-functional teams to achieve IND filing with FDA, and progress of pipeline products from preclinical to clinical studies. Cheuk Ka has program management and translational research experience in biotech companies and academic institutes.